Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 8/20 | 0.46 |
| ▸ | CPA1 | P15085 | 5/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22810961 | 1.00 | POLB (0.49) | POLBACEALDH1A1HSD17B10MME | |
| SCHEMBL21699252 | 1.00 | POLB (0.49) | POLBACEALDH1A1HSD17B10MME | |
| SCHEMBL2734908 | 1.00 | POLB (0.49) | POLBACEALDH1A1HSD17B10MME | |
| SCHEMBL15313443 | 1.00 | POLB (0.49) | POLBACEALDH1A1HSD17B10MME | |
| SCHEMBL18912329 | 0.93 | GAA (0.54) | POLBALDH1A1HSD17B10GAALMNA | |
| SCHEMBL19647312 | 0.93 | GAA (0.54) | POLBALDH1A1HSD17B10GAALMNA | |
| SCHEMBL22600820 | 0.90 | NPC1 (0.44) | ACEMMEGAALMNAKMT2A | |
| SCHEMBL26765974 | 0.90 | NPC1 (0.44) | ACEMMEGAALMNAKMT2A | |
| SCHEMBL22476513 | 0.89 | GAA (0.42) | ACEALDH1A1HSD17B10GAA | |
| SCHEMBL2755704 | 0.89 | ALDH1A1 (0.52) | POLBACEALDH1A1HSD17B10MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393790-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| US-8557780-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8466260-B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466260-B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130136756-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | SEATTLE GENETICS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8362213-B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120141509-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110171125-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-7834154-B2 | Anti-ROBO4 antibodies and uses therefor | GENENTECH, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-7745394-B2 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745394-B2 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7723485-B2 | engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids; Cys engineered anti-MUC16 antibodies (Ab) containing a heavy chain sequence, conjugated with one or more drug moieties through a linker; diagnostic and therapeutic uses | GENENTECH, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080311134-A1 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | GENENTECH, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080247951-A1 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136756-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | CD2BP2, IGSF11, PA2G4 | POLB 4076/4885ACE 4734/4885ALDH1A1 1372/4885 |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | POLB 3920/4885ACE 3491/4885ALDH1A1 3456/4885 |
| US-20210393790-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | POLB 1625/4885ACE 4357/4885ALDH1A1 1130/4885 |
| US-20110171125-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | POLB 3920/4885ACE 3277/4885ALDH1A1 3561/4885 |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | POLB 3920/4885ACE 3277/4885ALDH1A1 3561/4885 |
| US-20120141509-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | POLB 3920/4885ACE 3491/4885ALDH1A1 3456/4885 |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | POLB 4455/4885ACE 3395/4885ALDH1A1 3798/4885 |
| US-20080311134-A1 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | MUC1, PDIA6, LNPEP | POLB 4163/4885ACE 3599/4885ALDH1A1 721/4885 |
| US-20080247951-A1 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR | IGSF11, MRPS18A, ANXA4 | POLB 3002/4885ACE 3762/4885ALDH1A1 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.